Microbot Medical Inc.
NASDAQ:MBOTMedical - Instruments & Supplies
-$0.06 today
- Market cap
- $65.73M
- Beta
- 1.04
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.21
Volume 0.87M
Average 1.60M
MBOT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Microbot Medical Inc.NASDAQ: MBOT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $12K fell 20.0% year over year, ahead of the -43.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 20.0% from the prior quarter. Over 3 fiscal years it compounded at -22.8% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -20.0% holds above the trailing-twelve-month pace of -43.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 47K USD
- Year-over-year change
- -48.4%
- 4-year CAGR
- -11.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47K | -48.4% |
| FY2024 | 2024-12-31 | 91K | -14.2% |
| FY2023 | 2023-12-31 | 106K | +3.9% |
| FY2022 | 2022-12-31 | 102K | +34.2% |
| FY2021 | 2021-12-31 | 76K | — |
Depreciation & Amortization vs competitors
How MBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -43.6% is the 8th highest of 10, against a peer median of -5.9%.
- Depreciation & amortization amounts to 41.9% of revenue for MBOT, versus a peer median of 4.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $14.55M USD | -5.9% | +14.0% | 4.8% | |
| LTM Mar 2026 | $2.15M USD | +48.5% | +53.1% | 3.0% | |
| LTM Mar 2026 | $1.45M USD | -11.2% | +13.6% | 1079.1% | |
| LTM Mar 2026 | CA$526.63K CAD | +1.5% | -0.7% | 317.1% | |
| LTM Mar 2026 | $452K USD | +12.2% | +3.6% | — | |
| LTM Mar 2026 | $168K USD | -72.2% | -41.8% | 2.4% | |
| LTM Mar 2026 | $121K USD | -27.5% | +27.8% | — | |
| LTM Mar 2026 | CA$103.77K CAD | -69.2% | -22.6% | — | |
| LTM Mar 2026 | $44K USD | -43.6% | -22.8% | 41.9% | |
| LTM Mar 2026 | $16.88K USD | +36.5% | +20.6% | — | |
| Peer median (excluding MBOT) | — | -5.9% | +13.6% | 4.8% | |
Competitors are the stored peer set for MBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (11.31M) | (13.17M) | (10.74M) | (11.44M) | (13.14M) |
| Depreciation & Amortization | 76K | 102K | 106K | 91K | 47K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.39M | 1.75M | 1.39M | 1.35M | 1.06M |
| Change in Working Capital | 497K | (228K) | (11K) | 942K | (1.01M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | (584K) |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 497K | (228K) | (11K) | 942K | (424K) |
| Other Non-Cash Items | 1.39M | (7K) | 718K | 234K | 0 |
| Operating Cash Flow | (9.35M) | (11.55M) | (8.53M) | (8.83M) | (13.05M) |
| Capital Expenditures | (69K) | (84K) | (33K) | (25K) | (60K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (3.75M) | (10.06M) | (5.12M) | (82.93M) |
| Sales of Investments | 3.27M | 0 | 12.06M | 6.68M | 10.6M |
| Other Investing Activities | 0 | (3K) | 3K | 0 | 0 |
| Investing Cash Flow | 3.2M | (3.84M) | 1.97M | 1.54M | (72.38M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 4.32M | 6.56M | 7.94M | 86.24M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 0 | 4.32M | 6.56M | 7.94M | 86.24M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.15M) | (11.06M) | (2K) | 646K | 810K |
| Free Cash Flow | (9.42M) | (11.63M) | (8.57M) | (8.85M) | (13.11M) |
Microbot Medical Inc.
NASDAQ:MBOT
Intrinsic Alpha fair value
Locked
Current Price
$0.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.